B

BeOne

Global oncology therapeutics discovery, development, manufacturing

Regional Clinical Study Manager

Full-Time
$136.4k - $181.4k/yr+ Annual bonus plan + Discretionary equity awards + Employee Stock Purchase Plan
Senior
Bachelor's
Remote in USA
RemoteTravel may be required as needed.
Biology & BiotechClinical Research Operations

About the job

Requirements
  • A bachelor's degree in a scientific or healthcare discipline is required; exceptions may be made for candidates with relevant clinical operations experience.
  • Six or more years of progressive experience in clinical research within the biotechnology, pharmaceutical, or contract research organization industry.
  • Proven clinical research experience, including relevant experience as a team lead in clinical functions.
  • Proficiency with Microsoft Office and project planning applications.
Responsibilities
  • Be accountable for regional study delivery with appropriate inspection readiness and quality, within agreed timelines and budget.
  • Act as regional lead for multiple studies across an indication or program as required.
  • Lead the regional clinical operations team, including external partners working at a regional level, and act as the point of escalation for resolving issues within the region for the assigned study.
  • Ensure regional deliverables align with overall study goals.
  • Contribute to developing regional tools and lead the development of work instructions and standard operating procedures as required.
  • Lead the regional clinical operations team, ensure effective decision-making, and act as the point of escalation for issues within the region for the assigned study.
  • Lead external vendors involved in regional study delivery.
  • Collaborate with regional stakeholders and provide regular regional study progress updates to senior management and the Global Clinical Study Manager as required.
  • Represent the regional study team at internal meetings and cross-functional Clinical Study Team meetings.
  • Lead regional operations meetings with regional study team members.
  • Demonstrate therapeutic-area knowledge and expertise.
  • Lead planning and management of assigned clinical studies in the region from feasibility through closeout, in line with global study timelines.
  • Generate, manage, and maintain high-quality regional study start-up and recruitment timelines, and track progress against them.
  • Ensure regional operational feasibility; drive trial feasibility, country allocation, and site selection for the assigned region with feasibility managers, country heads, medical affairs, and other stakeholders.
  • Provide regional input on global study plans as required.
  • Ensure timely availability of local adaptations of global study documents, such as informed consent forms, collaborating with stakeholders to enable timely submissions to regulatory authorities and ethics committees/institutional review boards.
  • Account for study submissions in assigned countries in collaboration with the regional study start-up team and regulatory affairs.
  • Ensure regional and country information in study systems and tools is entered and kept up to date.
  • Collaborate with regional clinical research associates to ensure proper site execution, and review and sign off on monitoring reports.
  • Work with regional and country teams to ensure the country- and site-level Trial Master File is created, maintained, and regularly quality-controlled according to the study Trial Master File quality-control plan.
  • Provide regional drug-inventory input to Global Clinical Supplies, review local drug labels, and provide input on local regulatory approval and reimbursement status of comparator drugs used in regional countries.
  • Manage regional trial data collection and drive data entry and query resolution.
  • Support Clinical Study Report planning and execution as required, in collaboration with the Global Clinical Study Manager and Medical Writing.
  • Handle escalated site issues in the region in collaboration with stakeholders such as country heads.
  • Monitor regional study activities for compliance with the study protocol, standard operating procedures, International Council for Harmonisation/Good Clinical Practice, and other relevant regulations.
  • Ensure regional study inspection readiness throughout the study life cycle.
  • Inform the Global Clinical Study Manager of study issues, evaluate their impact, and ensure solutions are implemented.
  • Prepare sites for quality assurance audits and inspections, and drive responses to audit and inspection findings as appropriate.
  • Collaborate with Clinical Study Team members and colleagues to share cross-team and site learnings and best practices.
  • Lead improvements and partner with Clinical Study Team members to enhance the efficiency and quality of assigned study work.
  • Lead development, optimization, and review of work instructions and standard operating procedures as required.
  • Work with the sourcing team to select and manage regional study vendors.
  • Manage regional study budgets.
  • Work with Clinical Business Operations on investigator fees, site-payment issues, and patient travel reimbursement activities.
  • Identify and manage regional team resource needs and establish contingency plans for key resources.
  • Monitor regional resource utilization over the study life cycle and liaise with functional managers as needed.
  • Provide performance feedback on team members as required and mentor junior team members; line-management responsibilities may be assumed as required.
Desired Qualifications
  • A higher degree is preferred.
  • Experience as a clinical research associate is preferred.

About the company

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
  • August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
  • Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.

What critics are saying

  • BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
  • Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
  • AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.

What makes BeOne unique

  • BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
  • BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
  • Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • 401(k) Retirement Plan
  • Wellness Program
  • Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

-6%

2 year growth

-1%
Associated Press
Oct 6th, 2026
Onco360 partners with BeOne Medicines to distribute Beqalzi for relapsed mantle cell lymphoma

Onco360, an independent specialty pharmacy, has been selected as a pharmacy partner by BeOne Medicines for Beqalzi (sonrotoclax). The drug is indicated for treating adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor. Beqalzi is a BCL-2 protein inhibitor. In a Phase 1/2 study of 103 adult patients with relapsed/refractory mantle cell lymphoma, the drug achieved an overall response rate of 52.4%, with a median time to response of 1.9 months. The median duration of response was 15.8 months. Onco360 is headquartered in Louisville, Kentucky, and operates as a flagship brand of PharMerica Corporation.

Yahoo Finance
Sep 4th, 2026
BeOne secures US pharma-tariff exemption after $1B+ manufacturing investment, but pricing concessions raise margin concerns

BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.

Yahoo Finance
Aug 13th, 2026
Revolution Medicines shares rise 6.2% on BeOne-funded Phase 3 RAS(ON) deal

Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.

Yahoo Finance
Aug 5th, 2026
BeOne Medicines Q2 revenue up 30% to $1.7B as BRUKINSA sales top $1.2B globally

BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.

Yahoo Finance
Jul 23rd, 2026
BeOne CEO sells $34.6M in stock while retaining 50M+ shares

John Oyler, chief executive officer of BeOne Medicines AG, sold 109,713 American Depositary Shares worth $34.6 million on 20 and 21 July 2026, according to SEC filings. The transactions were executed under a Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains a substantial ownership position exceeding 50.4 million total shares through various holdings. These include 28.2 million shares held through Oyler Investment LLC and 9.5 million shares in a Roth IRA account. The shares were sold at a weighted average price of $315.28. BeOne Medicines is a commercial-stage oncology biopharmaceutical company with $5.7 billion in trailing twelve-month revenue and a market capitalisation of $34.2 billion.